pI: 8.4209 |
Length (AA): 1482 |
MW (Da): 177394 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
6 | 1150 | 5wtk (A) | 27 | 1382 | 24.00 | 0.000022 | 0.99 | 0.587105 | 1.58 |
1013 | 1481 | 3lij (A) | 38 | 512 | 32.00 | 0 | 1 | 0.666464 | -0.35 |
1304 | 1482 | 3mse (B) | 1 | 179 | 79.00 | 0 | 1 | 0.943283 | -0.89 |
1340 | 1398 | 4gft (A) | 141 | 199 | 23.00 | 0.65 | 0.99 | 0.464811 | -1.51 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Male gametocyte. | Yeoh LM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | 16 hs Trophozoite, Erthyrocytic stages, Female gametocyte. | Otto TD Yeoh LM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Gametocyte, Ookinete, 22 hs Schizont. | Otto TD |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | 4 hs Ring. | Otto TD |
Otto TD | A comprehensive evaluation of rodent malaria parasite genomes and gene expression. |
Yeoh LM | Comparative transcriptomics of female and male gametocytes in Plasmodium berghei and the evolution of sex in alveolates. |
Ortholog group members (OG5_146625)
Species | Accession | Gene Product |
---|---|---|
Cryptosporidium hominis | Chro.40377 | hypothetical protein |
Cryptosporidium parvum | cgd4_3330 | hypothetical protein |
Neospora caninum | NCLIV_061660 | CAM kinase, CDPK family, putative |
Plasmodium berghei | PBANKA_0925500 | calcium-dependent protein kinase 6 |
Plasmodium falciparum | PF3D7_1122800 | calcium-dependent protein kinase 6 |
Plasmodium knowlesi | PKNH_0920600 | calcium-dependent protein kinase 6, putative |
Plasmodium vivax | PVX_091755 | calcium-dependent protein kinase 6, putative |
Plasmodium yoelii | PY04265 | Plasmodium falciparum CDPK2 protein-related |
Toxoplasma gondii | TGME49_218720 | calcium-dependent protein kinase CDPK6 |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
PBANKA_0925500 this record | Plasmodium berghei | Slow | plasmo |
TGME49_218720 | Toxoplasma gondii | Essentiality uncertain | sidik |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Zea mays | CaM kinase I alpha | 492 aa | 28.4% | 416 aa | Compounds | References |
Rattus norvegicus | Cell division protein kinase 5 | 292 aa | 28.1% | 249 aa | Compounds | References |
Homo sapiens | Cyclin-dependent kinase 1/cyclin B1 | 297 aa | 30.1% | 239 aa | Compounds | References |
Triticum aestivum | Calcium dependent protein kinase | 548 aa | 29.4% | 439 aa | Compounds | References |
Patiria pectinifera | Cdc2 | 300 aa | 25.3% | 304 aa | Compounds | References |
Rattus norvegicus | MAP kinase p38 alpha | 360 aa | 28.9% | 294 aa | Compounds | References |
Rattus norvegicus | Mitogen-activated protein kinase 1 | 358 aa | 29.8% | 312 aa | Compounds | References |
Oryctolagus cuniculus | Cyclin-dependent kinase 4 | 189 aa | 33.1% | 157 aa | Compounds | References |